Ras
Ras is the name given to a family of related proteins which is ubiquitously expressed in all cell lineages and organs. All Ras protein family members belong to a class of protein called small GTPase, and are involved in transmitting signals within cells. Ras is the prototypical member of the Ras superfamily of proteins, which are all related in 3D structure and regulate diverse cell behaviours. When Ras is 'switched on' by incoming signals, it subsequently switches on other proteins, which ultimately turn on genes involved in cell growth, differentiation and survival. As a result, mutations in ras genes can lead to the production of permanently activated Ras proteins. This can cause unintended and overactive signalling inside the cell, even in the absence of incoming signals. Because these signals result in cell growth and division, overactive Ras signaling can ultimately lead to cancer. The 3 Ras genes in humans (HRAS,KRAS, and NRAS) are the most common oncogenes in human cancer; Ras inhibitors are being studied as a treatment for cancer, and other diseases with Ras overexpression.
Ras Isoform Specific Products
All Product Categories
-
Ras Related Products (749)
Related Products (749)
-
Antibodies (36)
-
Ras Isoform Comparison
-
KRAS-IN-61
0 ImagesCat. No.: HY-187519KRAS-IN-61 is an orally effective pan-KRAS inhibitor that potently inhibits SOS1-mediated KRAS nucleotide exchange (IC50 <10 nM for KRAS G12D/G12V/G12C/WT). KRAS-IN-61 inhibits pERK signaling and cell proliferation in KRAS-mutant tumor cells. KRAS-IN-61 can inhibit tumor growth in vivo. KRAS-IN-61 can be used in studies of KRAS mutation-related cancers, such as colorectal cancer.
-
KRAS inhibitor-22
0 ImagesCat. No.: HY-153412CAS No.: 2042365-57-9
-
KRAS G12C degrader-1
0 ImagesCat. No.: HY-153881CAS No.: 2768099-51-8KRAS G12C degrader-1 (compound 283) is a potent KRASG12C chaperone-mediated protein (CHAMP) degrader with DC50 < 100 nM. KRAS G12C degrader-1 binds to KRASG12C and HSP90, inducing ubiquitination and proteasomal degradation of KRASG12C. KRAS G12C degrader-1 can be used for research on KRASG12C-mutant cancers.
-
Aspafilioside B
0 ImagesCat. No.: HY-122465CAS No.: 131123-73-4Aspafilioside B is a steroidal saponin. Aspafilioside B is extractable from Asparagus filicinus. Aspafilioside B activates the ERK, c-Raf and p38 MAPK signaling pathways, and upregulates H-Ras and N-Ras. Aspafilioside B mediates G2/M cell cycle arrest by altering the expression of cell cycle regulatory proteins. Aspafilioside B induces Apoptosis. Aspafilioside B increases intracellular ROS levels. Aspafilioside B is applicable to research related to hepatocellular carcinoma.
-
KRAS inhibitor-13
0 ImagesCat. No.: HY-146543CAS No.: 2230873-96-6KRAS inhibitor-13 (compound 5-6) is a potent KRAS G12C inhibitor with an IC50 of 0.883 µM. KRAS inhibitor-13 shows p-ERK inhibition activities with IC50s of 5.9, >100 µM in MIA PaCA-2, A549 cells, respectively. KRAS inhibitor-13 has the potential for the research of pancreatic, colorectal, and lung cancers.
-
KRAS G12C inhibitor 44
0 ImagesCat. No.: HY-142946CAS No.: 2927439-07-2KRAS G12C inhibitor 44 (compound 54) is a potent and orally active KRAS G12C inhibitor. KRAS G12C inhibitor 44 shows anti-proliferation activities with IC50s of 0.016, 0.028 µM in MIA PaCA-2, H358 cells, respectively. KRAS G12C inhibitor 44 shows antitumor effects in vivo.
-
RMC-8839
0 ImagesCat. No.: HY-184892CAS No.: 2953305-55-8RMC-8839 is an orally active selective RAS (ON) G13C inhibitor with a Ki value of 28.3 nM. RMC-8839 disrupts the interaction between KRASG13C and RAF1 (RBD). RMC-8839 inhibits RAS-MAPK pathway signaling by reducing DUSP6 mRNA levels and pERK levels. RMC-8839 induces cytotoxicity, apoptosis (apoptosis) and antiproliferative effects in KRASG13C-mutated cells. RMC-8839 induces tumor stasis or regression in mice. RMC-8839 can be used in research related to non-small cell lung cancer.
-
KRAS G12C inhibitor 52
0 ImagesCat. No.: HY-147633CAS No.: 2761204-87-7KRAS G12C inhibitor 52 (Compound 7) is a KRAS G12C inhibitor.
-
Antitumor agent-60
0 ImagesCat. No.: HY-146432CAS No.: 865784-65-2Antitumor agent-60 (compound 20) is a potent antitumor agent, targeting RAS-RAF signaling pathway and binding to CRAF with a Kd value of 3.93 μM. Antitumor agent-60 induces apoptosis by blocking cell cycle at G2/M phase. Antitumor agent-60 enhances the level of p53 and ROS. Antitumor agent-60 causes oval and irregular nucleus in cancer cells. Antitumor agent-60 can suppress the growth of tumor to some extent in A549 xenograft model.
-
EGFR-IN-119
0 ImagesCat. No.: HY-163880EGFR-IN-119 (Compound 5l) is an inhibitor for EGFR with an IC50 of 84.3 nM. EGFR-IN-119 inhibits the cytotoxicity in lung cancer cell A549 with an IC50 of 1.34 μM. EGFR-IN-119 downregulates the expressions of EGFR, KRAS, and MAP2K genes, exhibits antioxidant activity through reduction of reactive oxygen species (ROS), and hyperpolarizes the mitochondrial membrane potential.
-
ISIS 2503 sodium scrambled negative control
0 ImagesCat. No.: HY-153488CISIS 2503 sodium scrambled negative control is the sequence scrambled negative control of ISIS 2503 sodium.
-
KRAS inhibitor-12
0 ImagesCat. No.: HY-146533CAS No.: 2230874-00-5KRAS inhibitor-12 (compound 6-1) is a potent KRAS G12C inhibitor with an IC50 of 0.537 µM. KRAS inhibitor-12 shows p-ERK inhibition activities with IC50s of 1.3, 3.7 µM in MIA PaCA-2, A549 cells, respectively. KRAS inhibitor-12 has the potential for the research of pancreatic, colorectal, and lung cancers.
-
KRAS G12D inhibitor 12
0 ImagesCat. No.: HY-143606CAS No.: 2648552-54-7KRAS G12D inhibitor 12 is a potent inhibitor of KRAS G12D. The Ras family of proteins is an important intracellular signaling molecule that plays an important role in growth and development. KRAS G12D inhibitor 12 has the potential for the research of KRAS G12D-mediated cancer (extracted from patent WO2021108683A1, compound 134).
-
eIF4E/eIF4G PPI-IN-1
0 ImagesCat. No.: HY-176288eIF4E/eIF4G PPI-IN-1 is an eIF4E/eIF4G interaction inhibitor with a KD of 20.2 μM for eIF4E protein. eIF4E/eIF4G PPI-IN-1 plays an antitumor role in multiple modes of action including regulating the activity of eIF4E by inhibiting the Ras/MAPK/eIF4E signaling pathway, apoptosis and cell migration. eIF4E/eIF4G PPI-IN-1 suppresses the growth of HepG2 xenografts in nude mice and was relatively nontoxic to mice.
-
SOS1-IN-7
0 ImagesCat. No.: HY-144211CAS No.: 2755415-30-4SOS1-IN-7 (compound 18-p1) is a potent SOS1 inhibitor with IC50s of 20 and 67 nM for SOS1-G12D and SOS1-G12V, respectively.
-
KRAS G12C inhibitor 46
0 ImagesCat. No.: HY-142948CAS No.: 2573769-23-8KRAS G12C inhibitor 46 (compound WX003) is a potent KRAS G12C inhibitor.
-
SOS1-IN-25
0 ImagesCat. No.: HY-179443CAS No.: 3092446-09-5
-
KRAS inhibitor-23
0 ImagesCat. No.: HY-160220SCAS No.: 2641747-55-7
